PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

006 is the extension study of 002. Ideally they want long-term...

  1. 73 Posts.
    lightbulb Created with Sketch. 85
    006 is the extension study of 002. Ideally they want long-term data from at least 750 out of the 938 participants that start the 002 trial but it’s hard to know exactly how many will remain 12+ months from now. So they’ve simply assumed a 20% attrition rate for the 002 trial due to covid and other reasons for conservatism.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.